Linagliptin (Trajenta®, Tradjenta™, Trazenta™, Trayenta™) is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once-daily use for the treatment of adults ...
Glyxambi® combines 10 mg or 25 mg empagliflozin with 5 mg linagliptin, with different, complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes. Empagliflozin removes glucose through the urine by blocking blood glucose re-absorption in the kidney, and ...
932-P: Clinical Efficacy, Safety, and Tolerability of Single-Pill Combination of Dapagliflozin and Linagliptin in Uncontrolled Indian Type 2 Diabetes Mellitus Patients—A Randomized Double-Blind Studydoi:10.2337/db24-932-PIntroduction: While Dapagliflozin and Linagliptin are known for robust glycaemic ...
440 Accesses 5 Citations Explore all metrics Abstract A sensitive, simple and validated thin-layer chromatography (TLC) method (method A) and a high-performance thin-layer chromatography (HPTLC) method (method B) have been developed for the simultaneous determination of linagliptin (LNG) and empa...
Separation was carried out on Symmetry® C18 column using methanol: 10 mM ammonium formate buffer (containing 0.2% formic acid) in a ratio of (95: 5, v/v) as mobile phase at flow rate 0.25 mL min−1. Quantification was performed with multiple reaction monitoring in positive ...
About 236 participants were randomly assigned to receive either a fixed-dose combination of dapagliflozin 10 mg plus linagliptin 5 mg tablets or a fixed-dose combination of dapagliflozin 10 ...
Patients with T2DM, with a stable dose of metformin ≥1000 mg/day as monotherapy for at least 3 months before screening, with inadequate glycemic control at screening were randomly assigned to either arm A (dapagliflozin 10 mg + linagliptin 5 mg) or arm B (linagliptin 5 mg) in a 1:1 ra...